Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bearish -25

Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know

AI-generated analysis

📉 A proposed 2027 federal budget revealed significant spending cuts for health agencies, causing several biotech and pharmaceutical stocks to fall in the afternoon session.

🏥 The Department of Health and Human Services (HHS) funding reduction includes a specific proposal to cut National Institutes of Health (NIH) funding by $5 billion.

🔬 As a critical source of research funding, the proposed NIH cuts introduce uncertainty for pharmaceutical and biotech firms' innovation and development pipelines.

📈 While Congress is unlikely to approve the full extent of the cuts, the proposal created enough market uncertainty to trigger price drops in several key stocks.

🧬 Guardant Health (NASDAQ:GH) fell 4%, while Organon (NYSE:OGN) declined by 4.6%.

⚗️ Drug development inputs companies Fortrea (NASDAQ:FTRE) and Charles River Laboratories (NYSE:CRL) dropped 3.4% and 3.6% respectively.

🔍 Diagnostics firm QuidelOrtho (NASDAQ:QDEL) suffered the largest decline in the group, falling 6.4%.

📊 Market volatility analysis suggests that today's move for QuidelOrtho is meaningful but does not fundamentally alter investors' perception of the business.

📉 QuidelOrtho shares have experienced extreme volatility with 42 intraday moves greater than 5% over the past year.

💸 Since the start of the year, QuidelOrtho has been down 44%, trading significantly below its 52-week high of $37.42 from May 2025.

🌍 Previous market reactions were driven by geopolitical uncertainty tied to the U.S.-Iran conflict and policy deadlines set by the Trump administration.

📉 Consumer confidence has also declined, with the University of Michigan's sentiment index sliding to a three-month low due to fears of prolonged conflict.

Bullish Signals
  • The article suggests that big price drops due to market overreaction can present good opportunities to buy high-quality stocks.
  • QuidelOrtho's volatility indicates the market views recent news as meaningful but not fundamentally damaging to its business perception.
  • Despite a 44% drop year-to-date, QuidelOrtho remains trading below its 52-week high of $37.42 from May 2025, implying significant upside potential if sentiment improves.
  • Charles River Laboratories shares fell only 3.6%, indicating relative stability compared to peers like QuidelOrtho which dropped 6.4%.
  • The article highlights that while Congress is unlikely to approve full budget cuts, any uncertainty creates a buying opportunity for undervalued healthcare stocks.
Risk Factors
  • A proposed $5 billion cut for the National Institutes of Health (NIH) creates uncertainty for the biotech and pharmaceutical sectors, which could impact innovation and development pipelines.
  • Despite Congress being unlikely to approve the full extent of the cuts, the proposal has introduced market uncertainty that drove several stocks down in the afternoon session.
  • Guardant Health (NASDAQ:GH) fell 4% following the news.
  • Organon (NYSE:OGN) fell 4.6% in reaction to the proposed federal spending cuts.
  • Fortrea (NASDAQ:FTRE) declined by 3.4% as testing and diagnostics services stocks were negatively impacted.
  • QuidelOrtho (NASDAQ:QDEL) experienced a significant 6.4% decline, with shares trading at $16.13, which is 56.9% below its 52-week high of $37.42 from May 2025.
  • Charles River Laboratories (NYSE:CRL) fell 3.6% in the afternoon session.
  • QuidelOrtho's stock has been extremely volatile with 42 moves greater than 5% over the last year, raising concerns about price stability.
  • QuidelOrtho is down 44% since the beginning of the year, indicating sustained investor skepticism and capital erosion.
  • Prolonged conflicts and rising oil prices have negatively impacted consumer confidence, further complicating the outlook for healthcare spending.
Full Analysis
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories stocks experienced declines in the afternoon session following the release of a proposed 2027 federal budget that included significant spending cuts for key health agencies. The budget request specifically targeted a reduction in funding for the Department of Health and Human Services (HHS), proposing a $5 billion cut for the National Institutes of Health (NIH). As the NIH is a critical source of funding for medical research, these reductions introduced uncertainty regarding innovation and development pipelines for pharmaceutical and biotech firms. While Congress is considered unlikely to approve the full extent of the proposed cuts, the proposal generated market volatility and price drops across the sector. Among the affected companies, QuidelOrtho saw the largest decline with shares falling 6.4%, while Organon dropped 4.6%, Guardant Health fell 4%, Charles River Laboratories decreased by 3.6%, and Fortrea saw a 3.4% decrease. The market reaction to the budget news has been interpreted as an overreaction, potentially presenting buying opportunities for high-quality stocks. However, QuidelOrtho's shares are noted as extremely volatile, having experienced 42 moves greater than 5% over the last year. Analysts suggest that despite today's meaningful move, it does not necessarily indicate a fundamental change in perception of the company's business model. In its recent performance, QuidelOrtho's shares have struggled significantly, dropping 44% since the beginning of the year. Currently trading at $16.13 per share, the stock is down 56.9% from its 52-week high of $37.42 reached in May 2025. Historical valuation context indicates that an investor who purchased $1,000 worth of QuidelOrtho shares five years ago would now hold a position valued at only $123.88. This decline follows previous market turbulence seen ten days ago when broader indices fell due to U.S.-Iran conflict concerns and policy deadlines under the Trump administration, which contributed to a sliding University of Michigan sentiment index that reached a three-month low.